Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort

Segura, Àlex G.; Martínez-Pinteño, Albert; Gassó, Patricia; Rodríguez, Natalia; Bioque, Miquel; Cuesta, Manuel J.; González-Peñas, Javier; García-Rizo, Clemente; Lobo, Antonio; González-Pinto, Ana; García-Alcón, Alicia; Roldán, Alexandra; Vieta, Eduard; Castro-Fornieles, Josefina; Mané Santacana, Anna; Saiz-Ruiz, Jerónimo; Bernardo, Miquel; Mas, Sergi

doi:http://dx.doi.org/10.1016/j.schres.2022.05.021

Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort

Citació

Segura ÀG, Martínez-Pinteño A, Gassó P, Rodríguez N, Bioque M, Cuesta MJ, et al. Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort. Schizophr Res. 2022 Jun; 244: 101-10. DOI: 10.1016/j.schres.2022.05.021

Resum

Objective: metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. Results: no major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR ≤ 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Conclusion: our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.